CagriSema is a subcutaneous injectable combination of cagrilintide and semaglutide that is currently in phase 3 trials.
Vidhi Patel, PharmD Candidate
Advertisement
Articles by Vidhi Patel, PharmD Candidate
Metformin may accelerate paclitaxel’s actions on cell replication in endometrial cancer.
Thiazolidinediones may change metabolic patterns and contribute to weight gain.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First OTC Acetaminophen–Naproxen Combination for 12-Hour Pain Relief
2
Two Weeks In: What the Medicare GLP-1 Bridge Actually Looks Like at the Counter
3
Thoracic Radiotherapy Added to Atezolizumab Raises Fatal Toxicity Risk in ES-SCLC
4
Up to 5 Cups of Coffee Daily Safe—and Beneficial—for Most Adults
5